2024年3月22日 · This report aims at developing an immunohistochemistry (IHC) assay to assess tumor-associated OX40 by utilizing morphology approach to understand OX40 expression in lymphoma cells, as opposed on tumor-infiltrate T-lymphocytes (TILs) present in TME.

2013年12月16日 · OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function, and survival of T cells.

2020年6月1日 · Activating CD137 and OX40 with agonistic mAbs stimulates the immune system due to their broad expression on CD4 + and CD8 + T cells and natural killer cells and has antitumor effects in preclinical models. Most TNFRSF agonist antibodies require crosslinking via Fcγ receptors (FcγR), which can limit their clinical activity.

OX40 (CD134, TNFRSF4) is a T cell costimulatory receptor that can potentiate T cell receptor (TCR) signaling during CD4 + and CD8 + T cell priming, effector cell differentiation and memory T cell recall responses. In preclinical mouse tumor models, surrogate anti-OX40 agonist antibodies have shown remarkable single agent anti-tumor efficacy, as ...

Human OX40 and OX40L protein expression was detected in B-hOX40/hOX40L mice by flow cytometry. Immune cell analysis: OX40 and OX40L humanization does not change the overall development, differentiation or distribution of spleen, lymph node, and blood immune cells in B-hOX40/hOX40L mice.

2017年8月30日 · Data from the paper published in Cancer Immunology Research showed that in mice, the simultaneous addition of anti-PD1 to anti-OX40 inhibited the T-cell specific positive effects of anti-OX40 and suppressed its therapeutic efficacy. The detrimental effect of the combination was a result of the induction apoptosis in antigen-specific T-cells.

OX40 (CD134) belongs to the tumor necrosis factor receptor super family and is mainly expressed by activated T lymphocytes. Agonistic anti-OX40 antibodies (Ab) have been developed as potential immunotherapies for the treatment of cancer.

2023年3月15日 · kn052是康宁杰瑞自主研发的pd-l1/ox40双特异性抗体，能够同时识别pd-l1与ox40，可有效阻断pd-l1与pd-1的相互作用，并激活ox40信号通路。 2022年2月，KN052的新药临床试验申请（IND）获得中国国家药品监督管理局（NMPA）批准，在中国开展Ⅰ期临床研究。

2013年12月15日 · Our findings clinically validate OX40 as a potent immune-stimulating target for treatment in patients with cancer, providing a generalizable tool to favorably influence the antitumor properties of circulating T cells, B cells, and intratumoral regulatory T cells.

2024年10月16日 · We demonstrated that OX40L-CAR-T regs were robustly activated in the presence of OX40L-expressing cells, leading to up-regulation of T reg suppressive proteins without induction of proinflammatory cytokine production.